Complete Title: A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous ...
The study concludes that increasing the dose of UPA offers no additional benefit, reinforcing that the standard 30 mg should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback